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Abstract It is well established that elevated blood pressure
constitutes a major risk factor for coronary heart disease,
arrythmias, heart failure, cerebrovascular disease, peripheral
artery disease and renal failure. Blood pressure level and the
duration of arterial hypertension (HTN) impact target organ
damage. Many studies in adults have demonstrated the role of
antihypertensive therapy in preventing cardiovascular (CV)
events. The so-called hard end-points, such as death, myocar-
dial infarction (MI) or stroke, are rarely seen in children, but
intermediate target organ damage, including left ventricular
hypertrophy, increased intima-media thickness and micro-
albuminuria, is already detectable during childhood. The goal
of antihypertensive treatment is to reduce the global risk of
CVevents. In the adult population stratification of CV risk is
based on blood pressure level, risk factors, subclinical target
organ damage and established CV and kidney disease. In-
creased CV risk begins early in the course of kidney disease,
and CV diseases are the most frequent cause of morbidity and
mortality in patients with chronic kidney disease (CKD).
Children with CKD are especially prone to the long-term
effects of CV risk factors, which result in high morbidity and
mortality in young adults. To improve the outcome, pediatric
and adult CKD patients require nephro- and cardioprotection.
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Introduction
Hypertension (HTN) is currently the single most important
contributor to death around the world—in both developed or
developing regions [1]. Elevated blood pressure (BP) is a
major risk factor for coronary heart disease, atrial fibrillation,
heart failure, cerebrovascular disease, peripheral artery disease
and renal failure. Worldwide, 7.6 million premature deaths
(13.5 % of all premature deaths) have been attributed to high
BP. Of the major cardiovascular (CV) events, about 54 % of all
strokes and 47 % of all ischemic heart disease cases can be
attributable to high BP [2]. An analysis of 23 HTN trials that
involved 193,424 adult patients showed a high rate of coronary
heart disease (41.1 %), stroke (30 %) and heart failure (28.9 %
of recorded major CVevents) among the patient cohorts [3].
The prevalence of HTN increases in adult populations,
mostly because of aging populations and lifestyle changes,
but also due to the obesity epidemic. Population-based data
from Europe and North America indicate that 30–45 % of the
adult general population suffers from HTN [4]. The observed
increase of HTN prevalence in children and adolescents has
been reported to be associated with obesity and lifestyle
changes. An important aspect of long-term prognosis is the
tracking phenomenon. Elevated BP and cholesterol levels and
obesity in children or teenagers persist into adulthood and
increase the risk for CVevents later in life [5]. The increasing
prevalence of HTN in children and adolescents should be a
warning signal to pediatricians that they must focus on the late
consequences of HTN. As shown by the data from the
Healthcare Cost and Utilization Project Kids’ Inpatient Data-
base, the frequency of HTN-associated hospitalizations during
the 10-year study period increased across all age groups [6].
The so-called hard end-points, such as death, myocardial
infarction (MI) or stroke, are rarely seen in children, but
intermediate target organ damage, including left ventricular
hypertrophy (LVH), increased intima-media thickness (IMT)
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and microalbuminuria, is already detectable during childhood.
The reasons for hospitalization also differ between adult and
pediatric hypertensive populations. In children with HTN the
most common second diagnoses are convulsive disorder,
headache, obesity and lupus erythematosus [6].
Despite rapid progress in dialysis techniques and medica-
tions (e.g. erythropoietin and growth hormone therapy), CV
mortality rates among the dialysis patient population remains
very high. In their foundational work, Foley et al. showed that
young dialyzed adults have the same CV mortality risk as
subjects aged >85 years in the general population [7]. Such
patients, as young adults who started renal replacement ther-
apy (RRT) in childhood, are especially prone to increased CV
mortality.
The prognostic significance of ambulatory BP measure-
ments is higher than that of office BP in predicting CVevents
and target organ damage. In a study by Torffvit [8], type 2
diabetic adult patients who had not achieved the goal of a
nighttime systolic BP (SBP) of <140 mm Hg had a 12.9-fold
higher risk of developing MI, a 3.9-fold increased risk of
uremia and a 2.7-fold increased risk of death than patients
who had achieved this goal. In addition, those patients who
did not reach the goal despite further treatment experienced
more serious changes in the kidneys caused by diabetes. Lurbe
et al. monitored 75 adolescents and young adults with diabetes
type 1 and normal urinary albumin excretion at the baseline
evaluation [9]. These authors found that the observed increase
of SBP during sleep (from 109.9 to 114.9 mm Hg) preceded
the development of microalbuminuria.
CV risk stratification
The European Society of Hypertension and the European
Society of Cardiology have published the Guidelines for the
Management of Arterial Hypertension. In adult populations the
stratification of CV risk is based on BP level, risk factors,
subclinical organ damage (SOD) and established CV disease
(CVD) and kidney disease. The categories are clearly defined.
The main risk factors include systolic and diastolic blood
pressure (DBP) levels, age (man >55 years, women >65 years),
smoking, dyslipidemia, fasting plasma glucose of 5.6–
6.9 mmol/l, abnormal glucose tolerance test, abdominal obesi-
ty and family history of premature CVD (man at age <55 years,
women at age <65 years). Despite the presence of one out of
the major risk factors (HTN, hypercholesterolemia, smoking),
the vast majority of young and middle-aged adults will not
experience an adverse CV event. In contrast, an adult patient
with HTN grade 1 or 2 and one to two risk factors has a
moderate CV risk, while evidence of three or more risk factors,
metabolic syndrome, SOD or diabetes stratifies the patient into
the high risk group.
Risk stratification using the SCORE (the Systemic Coro-
nary Risk Evaluation) Project risk charts is recommended for
each adult hypertensive patient [10]. The SCORE risk charts
can be used to estimate the 10-year risk of fatal CVD by
gender, age, SBP, total cholesterol and smoking status. Risk
charts based on SCORE were developed for both low- and
high-risk countries. In individuals at low or moderate risk
(SCORE 1–4 %) the search for SOD is encouraged. Sehestedt
et al. showed the role of detecting SOD in the estimation of
CV risk [11]. In healthy subjects the assessment of SOD
includes increased pulse wave velocity (a marker of increased
arterial stiffness), presence of atherosclerotic plaques, in-
creased urine albumin/creatinine ratio (a marker of vascular
damage) and increased LV mass (LVM), which predicts CV
death independent of SCORE [11].
The presence of an established CVD or renal disease
carries a very high CV risk, even in patients with normal
or high-normal BP. HTN is the main CV risk factor, how-
ever patients with chronic kidney disease (CKD) also have
many other uremia-related risk factors, such as inflamma-
tion, oxidative stress, increased renin–angiotensin–aldoste-
rone system (RAAS) activity, increased Ca × P product,
hyperphosphatemia, hyperparathyroidism, decreased Fetuin-
A, elevated asymmetric dimethylarginine plasma concentra-
tions, fluid overload and anemia [12]. These risk factors are
why patients with renal diseases in the adult population are
considered to be at very high CV risk—even those with high
normal BP. A panel of experts has included CKD among the
eight high-risk pediatric diagnoses associated with premature
CV risk. Moreover, intervention strategies for children with
CKD should be similar to the secondary prevention guidelines
for adults with established coronary disease [13].
This cluster of different risk factors multiplies the CV risk.
The coexisting risk factors differ depending upon age. In a study
by Flynn et al. involving a group of 351 children with HTN,
44 % were obese. The authors reported that the hypertensive
children under 6 years were less likely to be obese or to have
elevated cholesterol than school-age children or adolescents, but
they were more likely to have secondary HTN and a lower
glomerular filtration rate (GFR) [14]. Wilson et al. [15] studied
children with CKD and found that the incidence of different CV
risk factors increased with increasing body mass index. The
patient group in this study comprised obese children with
HTN, dyslipidemia and abnormal glucose metabolism [15].
The prevalence of CV risk factors was very high in children
on RRT. In a Turkish study 44 % patients on peritoneal dialysis
had uncontrolled HTN and 39 % had dyslipidemia [16].
CKD as well as essential HTN and obesity/metabolic syn-
drome are characterized by enhanced activity of the RAAS
and the sympathetic nervous system [17]. These systems not
only regulate BP but also contribute to CVabnormalities.
HTN in adults is defined as a SBP of >140 mmHg and/or a
DBP of >90mmHg [4]. Evidence from randomized controlled
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trials demonstrates that treatment-induced reductions in BP are
beneficial in patients with such BP values. A large number of
observational studies have demonstrated that CV morbidity
and mortality have a continuous relationship with both SBP
and DBP [18]. In adults, each 20-mm Hg increase in SBP or
10-mmHg increase in DBP doubles the death rates from stroke
and other CV causes. A meta-analysis of individual data for
one million adults revealed that the relationship between BP
and vascular mortality decreases steeply downwards, at least as
far as the normal SBP of 115 mm Hg and DBP of 75 mm Hg.
In children, BP increases with age and body size. Norma-
tive values for defining HTN have been determined on the
basis of BPmeasurements in a large reference population [19].
In that study, the cut-off point for detecting HTN in children
was defined as the 95th percentile for gender, age and height.
To date, there have been no multicenter long-term studies
assessing the impact of childhood BP level on clinically
apparent CV complications in adulthood. However, in youth
a graded increase in SOD parameters [carotid IMT (cIMT),
arterial stiffness, LVM index (LVMI) and decrease in diastolic




Hypertensive heart disease consists of both vascular and myo-
cardial changes. Various mechanisms are responsible for hyper-
tensive heart disease, including endothelial dysfunction and
coronary arteriolar constriction causing ischemia of the myocar-
dium, increased fibrosis, apoptosis and inflammatory changes
[21, 22]. A major role in structural remodeling of the heart is
played by cardiomyocyte and vascular smooth muscle cell
hypertrophy, the conversion of fibroblasts to myofibroblasts,
expansion of interstitial and perivascular collagen and decreased
intramyocardial capillary density. Biochemical stress via stretch-
activated ion channels leads to the intracellular transmission of
signals to the nucleus, thereby up-regulating hypertrophic gene
expression.
Fibrosis of the myocardium is an important risk factor for
arrhythmias. Interstitial fibrosis interferes with optimal cardiac
electrical conduction which establishes favorable conditions
for re-entry circuits. Rudolph et al. reported that 50 % of their
patients with HTN had myocardial fibrosis, measured as late
gadolinium enhancement [23]. In contrast to coronary heart
disease, these lesions were predominantly non-subendocardial.
In another study, treatment with angiotensin converting en-
zyme (ACE)-inhibitor demonstrated the efficacy of blocking
the RAAS in reducing myocardial fibrosis as estimated by
endomyocardial biopsy with measurement of the left ventricle
collagen volume fraction and myocardial hydroxyproline
concentration [24].
A study involving 1,454 pediatric dialysis patients found
that arrhythmias were the most common cardiac-related
events in these patients (19.6 %) [25]. Valvular heart disease
(11.7 %), cardiomyopathy (9.6 %), cardiac arrest (3.0 %) and
cardiac death (2.8 %) constituted the other cardiac-related
events. HTN doubled the risk of cardiac disease in this group.
Despite the fact that echocardiography is recommended as a
routine test to be performed in all hypertensive children [19],
this test was only performed in one-third of the children.
HTN induces a compensatory thickening of the ventricular
wall in an attempt to normalize wall stress, which results in
concentric LVH, which in turn decreases LV compliance and
LV diastolic filling, causing heart failure. Diastolic dysfunc-
tion develops in hypertensive patients even in the absence of
LVH. Impaired isovolumic relaxation leads to decreased ve-
locity of early diastolic filling. Doppler imaging of the mitral
inflow is a simple, noninvasive and repeatable method of
assessing LV diastolic filling. A low early/atrial (E/A) mitral
flow velocity ratio confers an increased risk of CV events in
Caucasian patients with essential HTN [26]. This risk in-
creases by 21 % for each 0.3 decrease of the age- and heart
rate-adjusted E/A ratio. Impaired LV diastolic function in
children with CKD is shown in the study of Mitsnefes et al.
[27]. In a study on children on dialysis, the indices of LV
relaxation and LV compliance were found to be significantly
associated with the LVMI. A reliable marker of diastolic
dysfunction, namely, the ratio of early mitral inflow to peak
early diastolic annular velocity measured by Tissue Doppler
(E/E′), was increased in the dialyzed and transplanted chil-
dren. The E/E′ ratio was significantly higher in patients with
elevated BP, indicating an association between HTN and
diastolic dysfunction [28]. In a group of 110 children on
peritoneal dialysis, LVMI as well as E/E′ correlated positively
with mean arterial pressure (MAP) and negatively with he-
moglobin and albumin levels and diuresis [29].
Left ventricular hypertrophy)
Research conducted on adults and children has revealed that
LVM is significantly determined by fat-free mass (FFM). To
avoid any incorrect interpretation of results when body surface
area in obese patients is used, it was suggested that height
raised to an exponential power of 2.7 should be used as an
equivalent of FFM. The Fourth Report recommends using a
single cut-off point (38 g/m2.7) to define LVH in children [30].
Khoury et al. performed M-mode echocardiography in 2,273
non-obese healthy children and established percentile charts
for LVM and LVMI depending on sex and age. The 95th
percentile for LVMI ranged from 80 g/m2.7 for newborns to
40 g/m2.7 for 11 year olds. These researchers recommended
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the identification of LVH based on the 95th percentile for
LVMI in children under 9 years of age, and in older children
the accepted cut-off point was an LVMI of >40 g/m2.7 in girls
and LVMI of >45 g/m2.7 in boys [31]. Foster et al. demon-
strated that the 95th percentile LVMI depends on the height
distribution of the reference population and proposed LVM-
for-height percentiles as a superior means of normalizing
LVM for body size [32]. In young children, the correct diag-
nosis of LVH is difficult to arrive at due to the small reference
samples and rapid changes in body size and heart mass. In
CKD, children suffer from growth retardation and body com-
position changes (malnutrition, overhydration). Borzych et al.
proposed using height age instead of chronological age to
calculate the LVMI [33].
LVH is an important SOD in hypertensive subjects and an
independent CV risk factor both in children and adult popu-
lations [34]. In several studies the relationship between LVM
and subsequent CV risk was found to persist after adjustment
for traditional risk factors. In the MAVI study, LVH doubled
the risk of CVevents. The following events developed during
follow-up in a group of uncomplicated subjects with essential
HTN: sudden cardiac death, MI, stroke, transient ischemic
attack, heart failure, new onset unstable angina, arterial occlu-
sive disease and progressive renal failure [34].
Left ventricle geometry can be classified into four catego-
ries: normal geometry, concentric remodeling [normal LVM,
increased relative wall thickness (RWT)], concentric hyper-
trophy (elevated LVM and RWT) and eccentric hypertrophy
(elevated LVM and normal RWT) [35]. Adult patients with
concentric remodeling and hypertrophy have the highest pe-
ripheral resistance, and those with eccentric hypertrophy have
a supernormal cardiac index, thereby demonstrating the role
of pressure and volume overload as mechanisms involved in
developing LVH. Moreover, in the group with concentric
remodeling, the highest peripheral resistance was accompa-
nied by reduced LV end-diastolic dimension, which suggests
that pressure overload is balanced by a decreased volume
load. In adults, concentric hypertrophy was found to be asso-
ciated with the highest risk of CVD. In concentric hypertro-
phy, the degree of impaired LV filling (left atrial afterload)
increases with increases in LV stiffness, which results in an
increase in the size and function of the left atrium.
Concentric and eccentric LVH have been detected in chil-
dren with primary HTN and in various studies in patients with
CKD at different stages of the disease [36–38]. In a group of
128 children on peritoneal dialysis followed by the Interna-
tional Pediatric Network (IPPN) Registry, SBP was signifi-
cantly lower in children with normal cardiac geometry than in
patients progressing to LVH orwith persistent LVH [39]. In the
multivariate analysis, obesity and HTN were independent risk
factors for persistent or de novo LVH. In the study performed
by Lurbe et al., LVH, defined as an LVMI of >95th percentile,
was detected only in patients with masked HTN and not in the
normotensive controls [40]. In another study involving CKD
patients, masked HTN (defined as normal clinical BP but
elevated in ambulatory BP measurements) was also linked to
a significant increase in the risk of LVH [41]. These results
highlight the need for performing regular ambulatory BP mea-
surements in children with CKD. As shown by the results of
the Escape study, concentric LVH is connected with subclini-
cal systolic dysfunction (impaired fractional shortening at the
midwall level) in children with CKD [42].
The treatment of HTN can result in the regression of LVH, as
shown in the Life study [43], which also showed that losartan
was more efficient than atenolol. In a meta-analysis by Fagard
et al., the regression of LVM was significantly less with β-
blockers (9.8 %) than with angiotensin receptor blockers
(12.5 %) [44]. Another important finding from this meta-
analysis was that all indices of systolic (LV fractional shorten-
ing and ejection fraction) and diastolic function (LVinflow ratio
of early to late diastolic filling) improved in response to anti-
hypertensive treatment. In children with CKD, treatment with
fixed high-dose ACE inhibition led to reduction in LVH prev-
alence and improvement in systolic function. The association
between an increase in midwall fractional shortening and a
reduction in BP has been discovered [45].
Prospective studies performed in adult hypertensive sub-
jects have found that LVH regression is associated with risk
reduction of major CV morbid events, such as stroke, MI, CV
death, atrial fibrillation, heart failure and even new-onset
diabetes mellitus [46, 47].
Heart failure
In adults, HTN is a very important risk factor for coronary
artery disease, arrhythmias (atrial and ventricular), MI and
systolic heart failure (Fig. 1). The impact of HTN on devel-
oping systolic heart failure is well established, and research
focus is currently directed towards diastolic heart failure.
The mechanisms underlying diastolic heart failure include
abnormal matrix dynamics, altered myocyte cytoskeleton,
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Fig. 1 In children, left ventricular (LV) hypertrophy with decreased left
ventricle compliance and diastolic dysfunction develops in the course of
hypertension—it is the first asymptomatic stage of diastolic heart failure.
In adults, hypertension is a main risk factor for coronary artery disease
(myocardial infarction), which results in myocardial damage and systolic
heart failure
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[48]. The stiffness of the left ventricle influences the volume–
pressure relationship during diastole, with small changes in
LV volume resulting in a greater rise in pressure. Increased
ventricular stiffness results from changes in extracellular ma-
trix and cytoskeleton isoforms. An increase in activation of
matrix metalloproteinases and tissue inhibitors of metallopro-
teinases can shift the type of collagen from type I to type III
which has increased stiffness and cross-linking. Titin, a thick
filament protein, is responsible for anchoring the thick fila-
ment to the z-disc in a sarcomere. Shifts to a stiffer isoform of
titin (N2B) alter the properties of the myofilament cytoskele-
ton and contribute to ventricular stiffness. Ischemia and chron-
ic conditions like diabetes with insulin resistance and in-
creased free fatty acid flux are responsible for an abnormal
energy balance in mitochondria and impaired removal of
calcium during diastole by the sarcoplasmic/endoplasmic re-
ticulum Ca2+ ATPase (SERCA2a) pump.
In the general population, the prevalence of congestive
heart failure (CHF) and LV diastolic dysfunction increases
with age [49]. Diastolic heart failure (DHF) accounts for more
than 50 % of the heart failure population and is also called
heart failure with normal LV ejection fraction (LVEF). By
definition, a patient with DHF presents the clinical signs and
symptoms of heart failure (fatigue, dyspnea, reduced exercise
tolerance, peripheral edema) with evidence of normal or mild-
ly abnormal systolic LV function (LVEF >50 %) and diastolic
LV dysfunction [50]. In the Framingham Study HTN preced-
ed the development of heart failure in 91 % of patients and
carried the greatest population-attributable risk for the devel-
opment of CHF of all the risks considered [51]. In addition,
HTN increased the risk of developing heart failure by about
twofold in men and threefold in women. In hypertensive
subjects MI, diabetes, LVH and valvular heart disease also
increased the risk of CHF. The authors underlined the impor-
tance of preventive strategies directed toward earlier and
aggressive BP control for reducing the incidence of CHF
and its associated high mortality.
Brain
In adults, the brain is an early target for organ damage by
elevated BP. HTN causes vascular brain injury directly [small-
vessel disease (SVD)] or by promoting atherosclerosis or
cardiac damage. HTN results in increased brain vascular
resistance and the loss of the physiological mechanism of
autoregulation. Hypertensive SVD is thought to be the main
cause of silent brain infarcts, which, by definition, lack clin-
ically overt stroke-like symptoms; rather, they are associated
with subtle deficits in physical and cognitive function. More-
over, the presence of silent infarcts more than doubles the risk
of subsequent stroke and dementia. In the adult population
75 % of strokes occur in patients aged >65 years. In a study in
6,105 individuals with previous stroke or transient ischemic
attack carried out by the PROGRESS Collaborative Group,
combination therapy with perindopril and indapamid reduced
systolic/diastolic BP by 12/5 mm Hg and stroke risk by 43 %.
A similar reduction in the risk of stroke in both hypertensive
and non-hypertensive subgroups was found [52].
In children, ischemic and hemorrhagic strokes occur at an
equally frequent rate, but their incidence is much lower than
that in adults, namely 1.2 to 13 cases per 100,000 children
under 18 years of age [53]. Clinical presentation in adoles-
cents is similar to that in adults, it mimics another disease in
younger children. The lack of awareness of a stroke in a child
is responsible for the longer time to diagnosis this event in
children than in adults, even in hospitalized patients. In adults,
age is the most important non-modifiable risk factor and HTN
the most important modifiable risk factor. The etiology of
stroke in children is mostly multifactorial and varied: congen-
ital and acquired heart disease, arteriovenous malformations
and sickle cell disease, thrombophilias and infectious diseases
such as varicella, sepsis, meningitis and even minor infection
[54]. Arteriovenous malformations, cavernous malformations
and aneurysms are the most common causes of pediatric
hemorrhagic stroke. HTN is also counted among hemorrhagic
stroke risk factors, yet since it rarely occurs in children it is
considered to be a less important risk factor. The most sensi-
tive method to diagnose acute ischemic stroke is brain mag-
netic resonance imaging, which requires sedation in younger
children. Nephrologic pediatric patients with vasculitis are at a
high risk of stroke. HTN, connective tissues diseases, a recent
infection and/or migraine headaches increase the risk of ver-
tebral artery dissection and cervical artery dissection, both of
which are a common cause of strokes in young adults after
injuries.
In children, an association has been reported between ele-
vated SBP and reduced scores on the digit span test, which is a
neuropsychological measure of attention and concentration
[55]. Single-center studies provide preliminary evidence that
hypertensive children manifest deficits on measures of
neurocognition, have an increased prevalence of learning
difficulties and have altered cerebrovascular reactivity (de-
creased ability to enhance cerebral blood flow in response to
increased neuronal activity) [56, 57].
Hypertension and vessels
Endothelial dysfunction
Endothelial cells play an important role in vessel homeostasis
and through their production of nitric oxide, prostacyclin and
thrombomodulin they regulate vasodilatation and fibrinolysis
and inhibit coagulation processes [58]. Both classic CV risk
factors (HTN, smoking, diabetes, elevated low-density
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lipoprotein (LDL)-cholesterol level, chronic inflammation) and
genetic factors influence endothelial function. The cumulative
effects of these various factors on endothelial cells have led to
the conclusion that endothelial function is a risk factor for the
circulatory system [59]. Endothelial dysfunction is an early
stage of atherosclerosis. Stimuli leading to vasorelaxation in
the presence of intact vascular endothelium (such as acetylcho-
line) produce vasoconstriction when acting directly on the
underlying smooth muscle cells in vascular areas with an
injured endothelium [60]. Elevated BP causes mechanical in-
jury to endothelial cells and concomitant endothelial dysfunc-
tion caused by other risk factors (hypercholesterolemia, uremia-
related risk factors) leads to vasoconstriction and to an increase
in BP. A decrease in endothelium-dependent vasodilatation can
be detected non-invasively by ultrasound imaging of the bra-
chial artery. In the study performed by the Rostock group,
decreased flow-mediated dilation of the brachial artery was
observed in pediatric CKD patients and correlated with an early
(preclinical) marker of atherosclerosis, increased cIMT [61].
Atherosclerosis and vascular stiffness
A broad spectrum of vascular pathology is observed in patients
with CKD. The arterial wall thickness increases due to exces-
sive pressure load, and different types of vascular calcification
are present. Dysregulation of the calcium–phosphate–parathor-
mone and vitamin D axis is thought to be the main mechanism
of vascular calcification in children with CKD [62]. The central
role in medial calcification is played by vascular smooth
muscle cells (VSMC) influenced by promoters and inhibitors
of calcification. Calcium- and phosphate-induced apoptosis
and osteo/chondrocytic differentiation of VSMC, as well as
increased deposition of VSMC-derived vesicles are found in
vessel rings from CKD patients [63]. In in vitro conditions,
elevated calcium is a more potent stimulus of calcification
induction than elevated phosphate. It is mostly the medial
calcification which causes arterial stiffness. In patients with
normal vessel structure the reflected wave arrives back at the
aortic root during diastole and increases coronary blood flow.
Reflected waves are faster in stiff vessels, resulting in an
increase in the central SBP and pulse pressure [64]. In adults,
increased pulse wave velocity is counted among subclinical
target organ damage. Intrafamilial heritability of various arte-
rial stiffness indexes and MAP was demonstrated in the Euro-
pean Project on Genes in Hypertension (EPOGH) study that
included 204 parents and 290 offspring [65].
Numerous studies have provided evidence that atheroscle-
rosis begins in childhood and is associated with the same risk
factors as in adults—obesity, HTN, dyslipidemia, diabetes
mellitus, cigarette smoking. Berenson et al. carried out autop-
sy studies within the framework of The Bogalusa Heart Study
and found that the early stages of atherosclerosis are already
present in childhood [66]. The authors found fibrous plaque
lesions and fatty streaks in the aortas and coronary arteries of
persons aged 6–30 years and correlated these with antemor-
tem risk factors. The lesions appeared earlier and were more
advanced in men. This Swedish group also found more ad-
vanced peripheral artery involvement in boys, who had thicker
intimal and medial wall layers in both the radial and dorsal
pedal arteries [67].
Increased IMT marks early stages of atherosclerosis in
children. In the patient cohort studied by Litwin et al., LVH
was already present in 46 % of patients with newly diagnosed
primary HTN. A standard antihypertensive treatment lowered
the BP and led to the regression of target organ damage as
evidenced by decreased LVMI and decreased cIMT [68]. The
association between cIMT and MAP, as well as high-
sensitivity C-reactive protein in peritoneal dialyzed children
has been reported. In this group of patients cIMT correlated
negatively with hemoglobulin and albumin levels, and with
Kt/V urea [16].
In many multicenter studies in adults the efficacy of statin
treatment in reducing the CV risk has been shown. Atheroscle-
rosis risk factors, such as HTN, hypercholesterolemia and
obesity, are already present in childhood, whereas their effects
can be seen in adults. Population screening tests for hypercho-
lesterolemia are recommended at the age of 9–11 and 17–19
years. If the family history shows either early occurrence of CV
events in parents and grandparents, or if overweight, obesity,
diabetes and/or HTN are present in a child, the lipid level
should be tested at the age of 2 years. Studies carried out in
children with familial hypercholesterolemia indicate the effica-
cy of statins in lowering the LDL-cholesterol level. The major-
ity of statins are recommended for children aged >10 years,
except for pravastatin (recommended for those aged >8 years).
Studies performed in children and in adults have demon-
strated a significant role of HTN in the progression of CKD.
However, different targets for BP control are recommended
for children and adults. In the Escape study, performed in 385
children with CKD, intensified BP control (MAP of <50th
percentile) improved renal survival, defined as the time to a
50 % decline in the GFR or progression to end-stage renal
disease (ESRD) [69]. In a large, community-based study
(Kidney Early Evaluation Program: KEEP) covering adult
participants with a GFR of <60 ml/min/1.73 m2, the risk of
progression to ESRD started at a SBP of 140 mmHg and was
highest among patients with a SBP of ≥150 mm Hg [70]. In
this group of 16,129 subjects, more than 33 % of participants
had uncontrolled HTN,mostly due to isolated systolic HTN. It
has been suggested that the increased stiffness of the arteries
of adult patients with CKD is responsible for the difficulties in
treating HTN.
The recently published The Fifth Joint Task Force of the
European Society of Cardiology and Other Societies on
Cardiovascular Disease Prevention in Clinical Practice rec-
ommended preventive efforts should be life-long, from birth
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(if not before) to old age. Prevention has been shown to
work: >50 % of the reductions seen in CHDmortality relate to
changes in risk factors and 40 % to improved treatments [10].
Future considerations
Long-term follow-up multicenter studies are necessary to as-
sess CV risk stratification in children and adolescents with
HTN and to develop standards for diagnostic and treatment
procedures. An addition point which should also be examined
is whether the application of screening tests for CV risk factors
and the implementation of adequate treatment will result in a
decrease of CVrisk in adulthood. Randomized controlled trials
are required to assess the safety and efficacy of different
antihypertensive drugs in reducing SOD in children. Modern
RRT results in lengthening the life expectancy of children and
adolescents with ESRD. Coexistence of many traditional and
uremia-related risk factors increases CV morbidity and mor-
tality. New research to understand the impact of specific
uremia-related factors on cardiac and vasculature remodeling/
injury is needed. Future studies to assess the efficacy and safety
of statin treatment in different cases of secondary hypercholes-
terolemia, for example CKD and obesity, are needed.
Summary
Hypertension is currently the biggest single contributor to
death around the world. Elevated BP represents an important
risk factor for CV diseases, such as coronary heart disease,
heart failure, stroke, peripheral artery disease and renal failure,
in adults. It is well established that subclinical target organ
damage (LVH, increased IMT, cognitive dysfunction,
microalbuminuria) is already present in childhood. A special
group of patients is that comprising children and adolescents
with CKD. In observational and multicenter studies, subclin-
ical target organ damage has been detected at early stages of
CKD; however, regression and progression of LVH or IMT
changes are possible. Ambulatory BP measurements and
echocardiography should be performed in children with
CKD on a regular basis in order to detect HTN and to monitor
therapy. The results of the European Escape trial show that
decreasing the BP to the low-normal range is associated with
slowing the progression of CKD in children. The goal of
antihypertensive treatment should not only be to normalize
the BP but also to prevent target organ damage. The major
concern in the management of hypertensive patients remains
the heightened rate of late consequences.
The impact of HTN on CV damage has been extensively
studied in large groups of adults—both in the general popula-
tion and the adult CKD population. Based on observational
and interventional studies, specific recommendations have
been developed for the treatment of HTN and other risk factors
(e.g. hypercholesterolemia) with the aim of reducing global
CV risk. Long-term follow-up multicenter studies are neces-
sary to assess CV risk stratification in children and adolescents
with HTN and to work out standards for diagnostic and treat-
ment procedures. New research to investigate the impact of
specific uremia-related factors on cardiac and vasculature
remodeling/injury are needed. The lack of comorbidities in
children allows us to study the influence of HTN on early
stages of organ damage—endothelial dysfunction in particular.
Children with CKD are at high risk of CV events, and
preventive strategies should be started early in the course of
renal disease.
Questions (answers are provided following the reference
list)
1. The pathophysiologicalmechanisms leading to hypertensive
heart disease are:
a. Interstitial and perivascular fibrosis
b. Myocardial ischemia
c. Changes in the extracellular matrix
d. All of the above
2. Which of the items listed below cannot be classified as
subclinical target organ damage:
a. Left ventricular hypertrophy (LVH)
b. Increased intima media thickness (IMT)
c. Hemorrhagic stroke
d. Increased pulse wave velocity
3. For cardiovascular risk stratification in adults, which of the
following are used;
a. Elevated blood pressure
b. Age
c. Glucose level
d. All of the above
4. In the general population:
a. Hypertension is the most important risk factor for
global mortality
b. The increase of 20 mm Hg in systolic blood pressure
(BP) or 10 mmHg in diastolic DBP is associated with
a doubling of cardiovascular risk
c. Target organ damage (LVH, increased IMT) is already
present in childhood
d. All of the above are true
5. The most common cardiovascular disease in pediatric
dialysis patients is:
a. Systolic heart failure
b. Diastolic heart failure
c. Arrhythmia
d. Cardiomyopathy
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